ARES
Market read
ARES accounts for 6.8% of the group's measured movement across 7.5 effective names. raw member direction is mixed; 7 of 12 session-normalized paths align to the upside. Capital-flow agreement is 15%, so confirmation is not yet clean. No verified headline preceded the measured group move.
ATRC moved materially before ARES. ARES crossed its material path threshold at 10:05 ET. BN, APO, BMY followed.
5 of 25 members in Biopharmaceuticals and Care are active. 0 of 3 disclosed connections are confirming.
Invalidation: The live read weakens if participation falls to 8 of 25 members or fewer.
Research brief
ARES accounts for 6.8% of the group's measured movement across 7.5 effective names. raw member direction is mixed; 7 of 12 session-normalized paths align to the upside. Capital-flow agreement is 15%, so confirmation is not yet clean. No verified headline preceded the measured group move.
No thresholded supportive filing evidence is available yet.
No thresholded adverse filing evidence is available yet.
Company research
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
No credible peer-relative valuation comparison is available yet.
Reported annual revenue and per-share history. This is accounting history, not a forecast.
What management says matters
“Fee related performance revenues for the six months ended June 30, 2025 were primarily attributable to incentive fees from a European direct lending fund that crystallized a deferred payment during the first quarter of 2025 due to the restructuring of its hol…”10-Q · Aug 7, 2026 ↗
“Financing Activities Six months ended June 30, 2026 2025 Net borrowings of Credit Facility $ 235,000 $ 1,115,000 Borrowings from Term Loan 399,415 — Dividends and distributions (1,036,513) (873,259) Taxes paid related to net share settlement of equity awards…”10-Q · Aug 7, 2026 ↗
“F-16 Table of Contents Ares Management Corporation Notes to the Consolidated Financial Statements (Continued) (Dollars in Thousands, Except Share Data and As Otherwise Noted) The non-controlling interests in Consolidated Funds represents a component of equity…”10-K · Feb 25, 2026 ↗
Valuation discipline
Price/sales — · EV/sales —. Comparisons use only industry-matched filing peers.
Scenarios are withheld for Financial Services until sector-specific earnings and capital metrics are available; generic revenue/P/S scaffolds would be misleading.
Price action
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
Jodie has not returned a relevant primary source or news item for ARES. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
Jodie has not yet found a suitable current-versus-prior filing comparison for ARES. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
“CLO-based investments The activity for the three months ended March 31, 2025 was primarily attributable to: • Interest and dividend income primarily included: (i) income of $2.1 million from our investments in CLOs and CLO-based investments; (ii) dividend inc…”
“While we recognized transaction gains for the three months ended September 30, 2025 due to the U.S.”
Depended on by
“On September 12, 2025 we entered into a Second Amendment to the credit and guaranty agreement (the “Amendment”), with Ares Management Credit funds, which amends the credit and guaranty agreement dated as of January 18, 2024.”
Filing peers
No filing peers are available for this name yet.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
ARES is currently a Participant in the organic co-movement group Biopharmaceuticals and Care. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
Context history
No durable theme membership has been observed for this name yet.